Ciladopa
Ciladopa (AY-27,110) je dopaminski agonist sa sličnom hemijskom strukturom sa dopaminom.[1] On je bio ispitivan kao mogući antiparkinsonski agens, ali su dalja ispitivanja prekinuta zbog moguće tumorogeneze.[2][3][4][5]
 | |
| IUPAC ime | |
|---|---|
2-{4-[(2S)-2-(3,4-dimetoksifenil)-2-hidroksietil]piperazin-1-il}ciklohepta-2,4,6-trien-1-on | |
| Klinički podaci | |
| Način primene | Oralno |
| Pravni status | |
| Pravni status |
|
| Identifikatori | |
| CAS broj | 80109-27-9  |
| ATC kod | none |
| PubChem | CID 133371 |
| ChemSpider | 117659 |
| UNII | D09L486R3J |
| Hemijski podaci | |
| Formula | C21H26N2O4 |
| Molarna masa | 370,44 g/mol |
| |
Reference
уреди- ^ Voith, K (1985). „The comparative long-term effects of ciladopa (AY-27,110), a chemically novel dopaminergic agonist, in 6-OHDA-lesioned and intact rats”. Psychopharmacology. 85 (4): 405—9. PMID 3927334. doi:10.1007/BF00429654.
- ^ Koller WC, Fields JZ, Gordon JH, Perlow MJ (1986). „Evaluation of ciladopa hydrochloride as a potential anti-Parkinson drug”. Neuropharmacology. 25 (9): 973—9. PMID 3774130. doi:10.1016/0028-3908(86)90190-5.
- ^ Weiner WJ, Factor SA, Sanchez-Ramos J, Berger J (1987). „A double-blind evaluation of ciladopa in Parkinson's disease”. Movement Disorders : Official Journal of the Movement Disorder Society. 2 (3): 211—7. PMID 3332914. doi:10.1002/mds.870020308.
- ^ Lieberman A, Gopinathan G, Neophytides A, Pasternack P, Goldstein M (1987). „Advanced Parkinson's disease: use of partial dopamine agonist, ciladopa”. Neurology. 37 (5): 863—5. PMID 3574692.
- ^ Lang, AE (1987). „Update on dopamine agonists in Parkinson's disease: "beyond bromocriptine"”. The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques. 14 (3 Suppl): 474—82. PMID 3315148.
